During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company’s manufacturing facility in Sydney, which he called “really a center of excellence for us, for the manufacture of inhaler products for the treatment of asthma and COPD.”
The Sydney facility primarily manufactures Pulmicort Respules. According to a report in In-Pharmatechnologist, AstraZeneca plans to add three manufacturing lines and 60 employees to meet growing demand from China.
Soriot added, “We intend through this incremental investment, we intend to generate about $2.6 billion of exports out of Australia to a great variety of markets including China. And these products are growing very very rapidly and we expect to generate even more investments in jobs in Australia over the next few years.”
Read the remarks from the meeting.
